Oxford Biomedica, a biotech firm spun out of the University of Oxford 31 years ago, is undergoing a significant transformation from an academic research-focused company into a fully commercial contract development and manufacturing organisation (CDMO). Known in financial markets as OXB, the company is expanding its footprint in the cell and gene therapy sectors with a focus on viral vector production for autoimmune disorders and cancer treatments.
Historically viewed as a UK-centric biotech pioneer reliant on legacy drug pipelines and royalty revenues, Oxford Biomedica gained wider recognition during the COVID-19 pandemic for manufacturing vaccines for AstraZeneca. Since then, it has rapidly shifted its business model to serve as a third-party developer and manufacturer, seeking to reduce reliance on the clinical risk associated with proprietary drug development. This approach has positioned OXB to capitalize on the growing demand for viral vectors used in gene therapies.
Under the leadership of CEO Frank Mathias, who joined in 2023 and previously led a successful turnaround at German biologics firm Rentschler Biopharma, Oxford Biomedica has accelerated its growth strategy. The company launched faster manufacturing platforms—in particular, its inAAVate and LentiVector lines—reducing production timelines for adeno-associated viral (AAV) vectors from 15 months to seven months. It has also broadened its technical capabilities to include all major viral vector types, increasing its market share in both AAV and adenoviral vector markets.
Expansion efforts have included the acquisition of manufacturing facilities in Europe and the United States, aided by a £60 million capital raise in 2025. The company’s full-year financial results for 2025 showed revenue growth of 31% to £168.7 million and its first positive operating EBITDA of £2.3 million. Its contracted revenue backlog also rose from £150 million to £204 million, indicating strong future earnings visibility. However, analysts remain cautious, forecasting modest earnings per share growth in the coming year and no dividends in the near term.
Oxford Biomedica briefly attracted buyout interest from Swedish investment firm EQT earlier this year, but no deal materialized. CEO Mathias has acknowledged the potential advantages of private equity ownership to accelerate growth, though any transaction would depend on an attractive offer. The company’s major shareholders include Briarwood Chase Management (15.4%), Institut Mérieux (10.8%), and Novo Holdings (11.1%), underscoring the importance of investor support in determining OXB’s future direction.
In recent months, Oxford Biomedica has strengthened its global partnerships, extending its strategic alliance with Bristol Myers Squibb and signing a licensing and option agreement with the Viral Vector Manufacturing Facility in Australia, enhancing its presence in the Asia-Pacific region. Mathias has articulated a bold vision for the company, targeting £500 million in annual revenue by 2030.
While Oxford Biomedica remains a higher-risk investment suited to those with a long-term outlook, its transition to a commercial CDMO with expanded manufacturing capabilities marks a critical pivot. The company appears poised to leverage its scientific heritage and manufacturing expertise to capture a larger share of the growing global cell and gene therapy market.